{"id":46312,"date":"2025-11-11T12:42:04","date_gmt":"2025-11-11T04:42:04","guid":{"rendered":"https:\/\/flcube.com\/?p=46312"},"modified":"2025-11-11T12:42:05","modified_gmt":"2025-11-11T04:42:05","slug":"brise-pharma-closes-rmb-200-m-series-a-to-fund-pivotal-phase-iii-trial-of-first%e2%80%91in%e2%80%91class-cgrp-small%e2%80%91molecule-analgesic-br005","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=46312","title":{"rendered":"Brise\u202fPharma Closes RMB\u202f200\u202fM Series\u202fA to Fund Pivotal Phase\u202fIII Trial of First\u2011in\u2011Class CGRP Small\u2011Molecule Analgesic BR005"},"content":{"rendered":"\n<p><strong>Brise Pharmaceuticals Co. Ltd.<\/strong>, a <strong>Sherpa Healthcare Partners<\/strong> portfolio company, announced the successful close of a <strong>Series\u202fA financing round exceeding RMB\u202f200\u202fmillion<\/strong>. The round was <strong>led by the Beijing Medical and Health Industry Investment Fund<\/strong> and included participation from <strong>INCE Capital, Guanghua Wutong, Proxima Ventures<\/strong>, with follow\u2011on commitments from existing backers <strong>Shunxi Fund<\/strong> and <strong>Qiming Venture Partners<\/strong>.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-deal-structure-amp-capital-allocation\">Deal Structure &amp; Capital Allocation<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Item<\/th><th>Detail<\/th><\/tr><\/thead><tbody><tr><td><strong>Total Capital Raised<\/strong><\/td><td><strong>&gt;\u202fRMB\u202f200\u202fmillion<\/strong> (\u2248\u202fUS$28\u202fmillion)<\/td><\/tr><tr><td><strong>Lead Investor<\/strong><\/td><td>Beijing Medical and Health Industry Investment Fund<\/td><\/tr><tr><td><strong>Co\u2011Investors<\/strong><\/td><td>INCE Capital, Guanghua Wutong, Proxima Ventures<\/td><\/tr><tr><td><strong>Follow\u2011On Investors<\/strong><\/td><td>Shunxi Fund, Qiming Venture Partners<\/td><\/tr><tr><td><strong>Primary Use of Proceeds<\/strong><\/td><td>\u2022 Initiate <strong>pivotal Phase\u202fIII<\/strong> trial of <strong>BR005<\/strong> (CGRP small\u2011molecule)<br>\u2022 Expand <strong>R&amp;D pipeline<\/strong> for novel analgesics targeting chronic pain<\/td><\/tr><tr><td><strong>Timeline<\/strong><\/td><td>Phase\u202fIII enrollment slated to begin <strong>Q1\u202f2026<\/strong><\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-scientific-amp-clinical-overview\">Scientific &amp; Clinical Overview<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>BR005:<\/strong> The <strong>first domestic, first\u2011in\u2011class<\/strong> calcitonin\u2011gene\u2011related peptide (CGRP) <strong>small\u2011molecule antagonist<\/strong> designed for <strong>severe chronic pain<\/strong>.<\/li>\n\n\n\n<li><strong>Target Indications:<\/strong><\/li>\n\n\n\n<li><strong>Head &amp; facial pain<\/strong> (e.g., cluster headache, trigeminal neuralgia)<\/li>\n\n\n\n<li><strong>Neuropathic pain<\/strong> (post\u2011herpetic neuralgia, diabetic neuropathy)<\/li>\n\n\n\n<li><strong>Musculoskeletal pain<\/strong> (osteoarthritis, chronic low\u2011back pain)<\/li>\n\n\n\n<li><strong>Pre\u2011clinical &amp; Early Clinical Data:<\/strong> Demonstrated <strong>\u2265\u202f70\u202f% reduction<\/strong> in pain scores versus placebo in Phase\u202fIIb proof\u2011of\u2011concept studies, with a <strong>favorable safety profile<\/strong> and <strong>once\u2011daily oral dosing<\/strong>.<\/li>\n<\/ul>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-market-opportunity\">Market Opportunity<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Chronic pain prevalence<\/strong> in China exceeds <strong>100\u202fmillion<\/strong> patients, representing a <strong>$15\u202fbillion<\/strong> unmet market.<\/li>\n\n\n\n<li><strong>CGRP antagonism<\/strong> is a validated mechanism in migraine; Brise\u2019s <strong>small\u2011molecule platform<\/strong> offers <strong>oral convenience<\/strong> and <strong>broader pain\u2011type applicability<\/strong> versus injectable antibodies.<\/li>\n\n\n\n<li>Successful Phase\u202fIII results could position BR005 as a <strong>first\u2011to\u2011market oral CGRP analgesic<\/strong>, opening <strong>global licensing<\/strong> and <strong>partnering<\/strong> opportunities.<\/li>\n<\/ul>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-investor-amp-strategic-implications\">Investor &amp; Strategic Implications<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li>The <strong>RMB\u202f200\u202fM<\/strong> infusion strengthens Brise\u2019s <strong>cash runway<\/strong> through <strong>Phase\u202fIII<\/strong> and early <strong>pipeline expansion<\/strong>, reducing dilution risk for existing shareholders.<\/li>\n\n\n\n<li>Participation by <strong>state\u2011linked Beijing Medical and Health Industry Investment Fund<\/strong> signals strong <strong>government endorsement<\/strong> for innovative pain\u2011management therapeutics.<\/li>\n\n\n\n<li><strong>Sherpa Healthcare Partners<\/strong> will continue to provide <strong>strategic guidance<\/strong> and <strong>access to China\u2019s regulatory network<\/strong>, accelerating market entry.<\/li>\n<\/ul>\n\n\n\n<p><strong>Forward\u2011Looking Statements<\/strong><br>This brief contains forward\u2011looking statements regarding Brise\u202fPharma\u2019s financing, development timeline, and commercial potential of BR005. Actual results may differ due to risks including clinical trial outcomes, regulatory approvals, and market acceptance.<a href=\"https:\/\/flcube.com\/\">-Fineline Info &amp; Tech<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Brise Pharmaceuticals Co. Ltd., a Sherpa Healthcare Partners portfolio company, announced the successful close of&#8230;<\/p>\n","protected":false},"author":1,"featured_media":46315,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[7,10],"tags":[4447,20],"class_list":["post-46312","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-company","category-deals","tag-brise-pharmaceuticals","tag-finance"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v23.6 (Yoast SEO v27.5) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>Brise\u202fPharma Closes RMB\u202f200\u202fM Series\u202fA to Fund Pivotal Phase\u202fIII Trial of First\u2011in\u2011Class CGRP Small\u2011Molecule Analgesic BR005 - Insight, China&#039;s Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"Brise Pharmaceuticals Co. Ltd., a Sherpa Healthcare Partners portfolio company, announced the successful close of a Series\u202fA financing round exceeding RMB\u202f200\u202fmillion. The round was led by the Beijing Medical and Health Industry Investment Fund and included participation from INCE Capital, Guanghua Wutong, Proxima Ventures, with follow\u2011on commitments from existing backers Shunxi Fund and Qiming Venture Partners.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=46312\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Brise\u202fPharma Closes RMB\u202f200\u202fM Series\u202fA to Fund Pivotal Phase\u202fIII Trial of First\u2011in\u2011Class CGRP Small\u2011Molecule Analgesic BR005\" \/>\n<meta property=\"og:description\" content=\"Brise Pharmaceuticals Co. Ltd., a Sherpa Healthcare Partners portfolio company, announced the successful close of a Series\u202fA financing round exceeding RMB\u202f200\u202fmillion. The round was led by the Beijing Medical and Health Industry Investment Fund and included participation from INCE Capital, Guanghua Wutong, Proxima Ventures, with follow\u2011on commitments from existing backers Shunxi Fund and Qiming Venture Partners.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=46312\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China&#039;s Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2025-11-11T04:42:04+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2025-11-11T04:42:05+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2025\/11\/1106.webp\" \/>\n\t<meta property=\"og:image:width\" content=\"1080\" \/>\n\t<meta property=\"og:image:height\" content=\"608\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=46312#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=46312\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"Brise\u202fPharma Closes RMB\u202f200\u202fM Series\u202fA to Fund Pivotal Phase\u202fIII Trial of First\u2011in\u2011Class CGRP Small\u2011Molecule Analgesic BR005\",\"datePublished\":\"2025-11-11T04:42:04+00:00\",\"dateModified\":\"2025-11-11T04:42:05+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=46312\"},\"wordCount\":400,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=46312#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/11\\\/1106.webp\",\"keywords\":[\"Brise Pharmaceuticals\",\"Finance\"],\"articleSection\":[\"Company\",\"Deals\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=46312#respond\"]}],\"copyrightYear\":\"2025\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=46312\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=46312\",\"name\":\"Brise\u202fPharma Closes RMB\u202f200\u202fM Series\u202fA to Fund Pivotal Phase\u202fIII Trial of First\u2011in\u2011Class CGRP Small\u2011Molecule Analgesic BR005 - Insight, China&#039;s Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=46312#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=46312#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/11\\\/1106.webp\",\"datePublished\":\"2025-11-11T04:42:04+00:00\",\"dateModified\":\"2025-11-11T04:42:05+00:00\",\"description\":\"Brise Pharmaceuticals Co. Ltd., a Sherpa Healthcare Partners portfolio company, announced the successful close of a Series\u202fA financing round exceeding RMB\u202f200\u202fmillion. The round was led by the Beijing Medical and Health Industry Investment Fund and included participation from INCE Capital, Guanghua Wutong, Proxima Ventures, with follow\u2011on commitments from existing backers Shunxi Fund and Qiming Venture Partners.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=46312#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=46312\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=46312#primaryimage\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/11\\\/1106.webp\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/11\\\/1106.webp\",\"width\":1080,\"height\":608,\"caption\":\"Brise\u202fPharma Closes RMB\u202f200\u202fM Series\u202fA to Fund Pivotal Phase\u202fIII Trial of First\u2011in\u2011Class CGRP Small\u2011Molecule Analgesic BR005\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=46312#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Brise\u202fPharma Closes RMB\u202f200\u202fM Series\u202fA to Fund Pivotal Phase\u202fIII Trial of First\u2011in\u2011Class CGRP Small\u2011Molecule Analgesic BR005\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Brise\u202fPharma Closes RMB\u202f200\u202fM Series\u202fA to Fund Pivotal Phase\u202fIII Trial of First\u2011in\u2011Class CGRP Small\u2011Molecule Analgesic BR005 - Insight, China&#039;s Pharmaceutical Industry","description":"Brise Pharmaceuticals Co. Ltd., a Sherpa Healthcare Partners portfolio company, announced the successful close of a Series\u202fA financing round exceeding RMB\u202f200\u202fmillion. The round was led by the Beijing Medical and Health Industry Investment Fund and included participation from INCE Capital, Guanghua Wutong, Proxima Ventures, with follow\u2011on commitments from existing backers Shunxi Fund and Qiming Venture Partners.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=46312","og_locale":"en_US","og_type":"article","og_title":"Brise\u202fPharma Closes RMB\u202f200\u202fM Series\u202fA to Fund Pivotal Phase\u202fIII Trial of First\u2011in\u2011Class CGRP Small\u2011Molecule Analgesic BR005","og_description":"Brise Pharmaceuticals Co. Ltd., a Sherpa Healthcare Partners portfolio company, announced the successful close of a Series\u202fA financing round exceeding RMB\u202f200\u202fmillion. The round was led by the Beijing Medical and Health Industry Investment Fund and included participation from INCE Capital, Guanghua Wutong, Proxima Ventures, with follow\u2011on commitments from existing backers Shunxi Fund and Qiming Venture Partners.","og_url":"https:\/\/flcube.com\/?p=46312","og_site_name":"Insight, China&#039;s Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2025-11-11T04:42:04+00:00","article_modified_time":"2025-11-11T04:42:05+00:00","og_image":[{"width":1080,"height":608,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/11\/1106.webp","type":"image\/png"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=46312#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=46312"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"Brise\u202fPharma Closes RMB\u202f200\u202fM Series\u202fA to Fund Pivotal Phase\u202fIII Trial of First\u2011in\u2011Class CGRP Small\u2011Molecule Analgesic BR005","datePublished":"2025-11-11T04:42:04+00:00","dateModified":"2025-11-11T04:42:05+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=46312"},"wordCount":400,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"image":{"@id":"https:\/\/flcube.com\/?p=46312#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/11\/1106.webp","keywords":["Brise Pharmaceuticals","Finance"],"articleSection":["Company","Deals"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=46312#respond"]}],"copyrightYear":"2025","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=46312","url":"https:\/\/flcube.com\/?p=46312","name":"Brise\u202fPharma Closes RMB\u202f200\u202fM Series\u202fA to Fund Pivotal Phase\u202fIII Trial of First\u2011in\u2011Class CGRP Small\u2011Molecule Analgesic BR005 - Insight, China&#039;s Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/flcube.com\/?p=46312#primaryimage"},"image":{"@id":"https:\/\/flcube.com\/?p=46312#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/11\/1106.webp","datePublished":"2025-11-11T04:42:04+00:00","dateModified":"2025-11-11T04:42:05+00:00","description":"Brise Pharmaceuticals Co. Ltd., a Sherpa Healthcare Partners portfolio company, announced the successful close of a Series\u202fA financing round exceeding RMB\u202f200\u202fmillion. The round was led by the Beijing Medical and Health Industry Investment Fund and included participation from INCE Capital, Guanghua Wutong, Proxima Ventures, with follow\u2011on commitments from existing backers Shunxi Fund and Qiming Venture Partners.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=46312#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=46312"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/?p=46312#primaryimage","url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/11\/1106.webp","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/11\/1106.webp","width":1080,"height":608,"caption":"Brise\u202fPharma Closes RMB\u202f200\u202fM Series\u202fA to Fund Pivotal Phase\u202fIII Trial of First\u2011in\u2011Class CGRP Small\u2011Molecule Analgesic BR005"},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=46312#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"Brise\u202fPharma Closes RMB\u202f200\u202fM Series\u202fA to Fund Pivotal Phase\u202fIII Trial of First\u2011in\u2011Class CGRP Small\u2011Molecule Analgesic BR005"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/11\/1106.webp","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/46312","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=46312"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/46312\/revisions"}],"predecessor-version":[{"id":46316,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/46312\/revisions\/46316"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/media\/46315"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=46312"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=46312"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=46312"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}